← Eichor
Condition: Transplant And Cell Therapy Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Transplant And Cell Therapy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05931263A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Ce
Phase 1 · 21 location(s) · TScan Therapeutics, Inc. · NCT05473910Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05776979REgulatory T Cell Therapy to Achieve Immunosuppression REduction
Phase 2 · 7 location(s) · Singulera Therapeutics Inc. · NCT06552169Submandibular Gland Stem Cell Transplantation
Phase 1 · 1 location(s) · University Medical Center Groningen · NCT04593589Moxibustion in the Treatment of Hemorrhagic Cystitis After Allo-HSCT
NA · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06241274TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantat
Phase 1 · 2 location(s) · Stanford University · NCT03943238Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Thera
Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06140966Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Phase 2 · 4 location(s) · Timothy Voorhees · NCT05786040Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treat
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT06769191The HOPE Biobank Resource (BMT CTN 2402 HOPE)
Phase N/A · 6 location(s) · Medical College of Wisconsin · NCT07227155TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic D
Phase 2 · 1 location(s) · Johns Hopkins All Children's Hospital · NCT04414046Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)
Phase 2 · 1 location(s) · Peking University · NCT06347653Evaluation of a PREHABilitation Protocol Using Adapted Physical Activity (APA) for Multiple Myeloma Patients Eligible fo
NA · 1 location(s) · Centre Hospitalier Henri Duffaut - Avignon · NCT06789003Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched Wit
Phase 2 · 1 location(s) · Minovia Therapeutics Ltd. · NCT06017869A Randomized Controlled Trial on the Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy in Subjects Wit
Phase 2 · 1 location(s) · Min Long · NCT07183761IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
Phase 2 · 1 location(s) · Dickran Kazandjian, MD · NCT06376526Autologous Non-cultured Epidermal Cell Suspension Transplantation in the Treatment of Vitiligo
NA · 1 location(s) · Peking University People's Hospital · NCT07187882A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Dar
Phase 3 · 270 location(s) · Janssen Research & Development, LLC · NCT05552222Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts
Phase 1 · 3 location(s) · Children's National Research Institute · NCT04691622CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Phase 3 · 1 location(s) · Peking University People's Hospital · NCT07441291EvaluatIon of Autologous Nucleus Pulposus Cells (aNPC) in Degenerative Disc Disease
Phase 1/Phase 2 · 1 location(s) · ASTEROGENE Biomedical Co. Ltd. · NCT07168603Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infec
Phase 1/Phase 2 · 1 location(s) · LucasBio · NCT07670468A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
EARLY_Phase 1 · 1 location(s) · First Affiliated Hospital of Guangxi Medical University · NCT05762510ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07106710Cultural Tailoring and Pilot Testing of an Inpatient Yoga Therapy Program for Cancer Patients Undergoing Hematopoietic S
NA · 3 location(s) · M.D. Anderson Cancer Center · NCT05681026Prospective Observational Cohort Study of Transplant and Cell Therapy Candidates and Recipients to Assess Social Determi
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT06431347Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
Phase 3 · 2 location(s) · Guangzhou Gloria Biosciences Co., Ltd. · NCT06514508Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Vir
Phase 4 · 1 location(s) · Beijing Children's Hospital · NCT07029958Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT03279094
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.